Arnoldo Barbosa

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

John J. Aponte, Pedro Aíde, Montse Renom et al. · The Lancet · 2007 · 274 citations

Vaccination, Vaccine Safety, Vaccine Development +6

Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of<i>Plasmodium falciparum</i>merozoites

Sheetij Dutta, J. David Haynes, J. Kathleen Moch et al. · Proceedings of the National Academy of Sciences · 2003 · 110 citations · Full text

Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the <i>Plasmodium falciparum</i> Apical Membrane Antigen 1 Expressed in <i>Escherichia coli</i>

Sheetij Dutta, P.V. Lalitha, Lisa A. Ware et al. · Infection and Immunity · 2002 · 107 citations · Full text

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

Mark E. Polhemus, Alan J. Magill, James F. Cummings et al. · Vaccine · 2007 · 100 citations

Malaria, Immunology, Parasite Genomics +5

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

Oscar Kashala, Roberto Amador, María V Valero-Bernal et al. · Vaccine · 2002 · 91 citations

Vaccination, Vaccine Development, Vaccine Target +8